Home RedHill Biopharma - 9 Late Stage Clinical Assets, $150 Million Market Cap - Is It Undervalued?
 

Keywords :   


RedHill Biopharma - 9 Late Stage Clinical Assets, $150 Million Market Cap - Is It Undervalued?

2015-09-11 14:41:16| Biotech - Topix.net

Every market day, we select up to 20 of our authors' top long and short ideas, exclusively for PRO subscribers. RedHill focuses on late stage oral gastrointestinal drugs; the company has two potential blockbusters in Phase 3 studies, 9 active clinical programs in total.

Tags: is it market million

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
23.11
23.11 WEEZER / maladroit 12\"
23.11
23.11 6'1ML REV-S
23.11speak up storys
23.11190mm LS0713FL
23.11That's Moulton
23.11SEED
More »